Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Immunic Inc

IMUX
1,14
0,04 (3,64%)
Pre Mercato
Ultimo aggiornamento: 14:51:23
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/12/202422:36EDGAR2Form 8-K - Current report
09/12/202414:30EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
06/12/202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202412:30PRNUSImmunic, Inc. to Participate in Investor Conference in..
14/11/202423:33EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202412:58EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202420:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202412:30PRNUSImmunic Announces Publication of Data From Phase 1/1b..
12/11/202415:31EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202413:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202412:45EDGAR2Form 8-K - Current report
07/11/202412:30PRNUSImmunic, Inc. Reports Third Quarter 2024 Financial Results..
31/10/202411:30PRNUSImmunic, Inc. to Announce Financial Results for the Third..
29/10/202411:30PRNUSImmunic to Participate in Industry, Scientific and Investor..
22/10/202412:45EDGAR2Form 8-K - Current report
22/10/202412:30PRNUSImmunic Announces Positive Outcome of Interim Analysis of..
18/9/202412:30PRNUSImmunic Presents Key Vidofludimus Calcium Data at the 40th..
10/9/202422:05EDGAR2Form 8-K - Current report
04/9/202412:30PRNUSImmunic Announces First Patient Enrolled in..
03/9/202414:30EDGAR2Form 8-K - Current report
28/8/202412:30PRNUSImmunic to Host Multiple Sclerosis R&D Day and Participate..
08/8/202413:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202412:45EDGAR2Form 8-K - Current report
08/8/202412:30PRNUSImmunic, Inc. Reports Second Quarter 2024 Financial Results..
01/8/202412:30PRNUSImmunic, Inc. to Announce Financial Results for the Second..
24/7/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/7/202412:40EDGAR2Form 8-K - Current report
24/7/202412:30PRNUSImmunic, Inc. Strengthens Its Board of Directors with the..
12/7/202414:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/7/202412:40EDGAR2Form 8-K - Current report
09/7/202412:30PRNUSImmunic Appoints Jason Tardio as Chief Operating Officer and..
12/6/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/5/202412:30PRNUSImmunic to Participate in Industry and Scientific..
24/5/202422:06EDGAR2Form S-3/A - Registration statement under Securities Act of..
08/5/202413:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202412:45EDGAR2Form 8-K - Current report
08/5/202412:30PRNUSImmunic, Inc. Reports First Quarter 2024 Financial Results..
06/5/202412:30PRNUSImmunic to Participate in Investor and Scientific..
01/5/202412:30PRNUSImmunic, Inc. to Announce Financial Results for the First..
30/4/202412:30PRNUSImmunic Announces Publication of Extended Data From Phase 2..
04/4/202412:30PRNUSImmunic to Host MS R&D Day and Participate in Investor..
20/3/202411:30PRNUSImmunic Receives Notice of Allowance for..
08/3/202422:05EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 1,10

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network